Cheung William, Guo Li, Cordeiro M Francesca
Glaucoma & Retinal Degeneration Research Group, UCL Institute of Ophthalmology, London, UK.
Optom Vis Sci. 2008 Jun;85(6):406-16. doi: 10.1097/OPX.0b013e31817841e5.
In recent years the focus of glaucoma research has shifted toward neuroprotection, as the traditional strategies of lowering intraocular pressure have been shown to be unable to prevent progressive vision loss in some glaucoma patients. As a result various neuroprotective drug-based approaches have been shown capable of reducing the death of retinal ganglion cells, which is the hallmark of glaucomatous optic neuropathy. There has been increasing evidence that glaucomatous neurodegeneration is analogous to other neurodegenerative diseases in the central nervous system, with recent work from our group elucidating a strong link between basic cellular processes in glaucoma and Alzheimer's disease. Additionally, there is a growing trend for using existing neuroprotective strategies in central nervous system diseases for the treatment of glaucoma. In fact, a trial treating patients with primary open-angle glaucoma with memantine, a drug approved for the treatment of Alzheimer's disease, has recently been completed. Results of this trial are not yet available. In this review, we will examine currently advocated neuroprotective drug-based strategies in the potential management of glaucoma.
近年来，青光眼研究的重点已转向神经保护，因为传统的降低眼压策略已被证明无法预防某些青光眼患者的视力进行性丧失。因此，各种基于神经保护药物的方法已被证明能够减少视网膜神经节细胞的死亡，而视网膜神经节细胞死亡是青光眼性视神经病变的标志。越来越多的证据表明，青光眼性神经退行性变与中枢神经系统中的其他神经退行性疾病类似，我们团队最近的研究阐明了青光眼的基本细胞过程与阿尔茨海默病之间的紧密联系。此外，将中枢神经系统疾病中现有的神经保护策略用于治疗青光眼的趋势也在增加。事实上，一项用美金刚治疗原发性开角型青光眼患者的试验最近已经完成，美金刚是一种被批准用于治疗阿尔茨海默病的药物。该试验结果尚未公布。在这篇综述中，我们将研究目前倡导的基于神经保护药物的策略在青光眼潜在治疗中的应用。
